BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 29040518)

  • 1. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.
    Camm AJ; Fox KAA; Peterson E
    Europace; 2018 Jan; 20(1):1-11. PubMed ID: 29040518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
    Cope S; Clemens A; Hammès F; Noack H; Jansen JP
    Value Health; 2015 Mar; 18(2):234-49. PubMed ID: 25773559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis.
    Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J
    Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
    Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS
    J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis.
    Fu W; Guo H; Guo J; Lin K; Wang H; Zhang Y; Wang Y; Shan Z
    J Cardiovasc Med (Hagerstown); 2014 Dec; 15(12):873-9. PubMed ID: 25304034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-vitamin K antagonist oral anticoagulants: new choices for patient management in atrial fibrillation.
    Saliba W
    Am J Cardiovasc Drugs; 2015 Oct; 15(5):323-35. PubMed ID: 26055615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
    Nielsen PB; Lane DA; Rasmussen LH; Lip GY; Larsen TB
    Clin Res Cardiol; 2015 May; 104(5):418-29. PubMed ID: 25416564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis.
    Mitchell SA; Simon TA; Raza S; Jakouloff D; Orme ME; Lockhart I; Drost P
    Clin Appl Thromb Hemost; 2013; 19(6):619-31. PubMed ID: 23698729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing the therapeutic equivalence of novel oral anticoagulants for thromboprophylaxis in orthopedic surgery and for prevention of stroke in atrial fibrillation.
    Messori A; Fadda V; Maratea D; Trippoli S; Marinai C
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):211-9. PubMed ID: 25295718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach.
    Verdecchia P; Angeli F; Bartolini C; De Filippo V; Aita A; Di Giacomo L; Poltronieri C; Lip GY; Reboldi G
    Expert Opin Drug Saf; 2015 Jan; 14(1):7-20. PubMed ID: 25311731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation.
    Lip GY; Kongnakorn T; Phatak H; Kuznik A; Lanitis T; Liu LZ; Iloeje U; Hernandez L; Dorian P
    Clin Ther; 2014 Feb; 36(2):192-210.e20. PubMed ID: 24508420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials.
    Patti G; Di Gioia G; Cavallari I; Nenna A
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 28029216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.